HC Wainwright & Co. Downgrades Karyopharm Therapeutics to Neutral, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 93.3%

Neg 93.3% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral and lowers the price target from $13 to $3.